PIK3CA and B-cell chronic lymphocytic leukemia: Initial success of idelalisib, the first approved PI3K-inhibitor for CLL, paved the development of a plethora of PI3K inhibitors, as recently reviewed by Kienle and Stilgenbauer (169).